Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab for severe pulmonary COVID-19
NL-OMON55089Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of otilimab in coronavirus disease 2019 (COVID-19) and coronavirus pneumonia, sponsored by GSK. Primary endpoint: Participants alive and free of respiratory failure at Day 28. Started Jul 2020; status: completed.
02
Drugs
otilimab
03
Conditions
coronavirus disease 2019 (COVID-19)coronavirus pneumonia
Beyond the preview
Go deeper on NL-OMON55089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55089.